GlassScriptPhysician profile
Ashley Sheehan
NPI 1225734163
$1,903.71
in general payments reported to CMS, 2019-2025
19 companies · $576 in 2025
The $576 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $717 · 2024: $611 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $627.38 | 2023-2025 | Belbuca, Xtampza |
| Averitas Pharma INC. | $482.42 | 2023-2025 | Qutenza |
| Vertos Medical, INC. | $166.52 | 2023 | Mild Device Kit |
| Protega Pharmaceutials INC | $113.96 | 2023-2024 | Roxybond |
| Boston Scientific Corporation | $93.40 | 2023-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Nalu Medical, INC. | $58.90 | 2025 | Nalu Neurostimulation System |
| Abbvie INC. | $57.84 | 2023-2025 | |
| Amgen INC. | $41.94 | 2024 | Krystexxa |
| Medtronic, INC. | $34.62 | 2025 | Synchromedii, Intellis Adaptivestim |
| Pfizer INC. | $34.30 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $32.34 | 2025 | |
| International Rehabilitative Sciences, INC | $29.50 | 2024-2025 | Rs 4i Plus Sequential Stimulator |
| Valinor Pharma, LLC | $26.35 | 2025 | Movantik |
| Convatec INC. | $25.53 | 2025 | |
| Nevro Corp. | $23.60 | 2024 | Senza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.50 | 2024 | Quviviq |
| Lundbeck LLC | $13.82 | 2025 | Vyepti |
| Fidia Pharma USA INC. | $13.07 | 2023 | Hymovis, Triluron |
| Foundation Fusion Solutions, LLC | $12.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Sheehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.